P19634 (SL9A1_HUMAN) Reviewed, UniProtKB/Swiss-Prot
Last modified
May 1, 2013.
Version 147.
History...
Names·Attributes·General annotation·Ontologies·Alt products·Sequence annotation·Sequences·References·Cross-refs·Entry info·DocumentsCustomize order
Names·Attributes·General annotation·Ontologies·Alt products·Sequence annotation·Sequences·References·Cross-refs·Entry info·DocumentsCustomize orderNames and origin
| Protein names | Recommended name: Sodium/hydrogen exchanger 1 Alternative name(s): APNH Na(+)/H(+) antiporter, amiloride-sensitive Na(+)/H(+) exchanger 1 Short name=NHE-1 Solute carrier family 9 member 1 | ||||
| Gene names |
| ||||
| Organism | Homo sapiens (Human) [Reference proteome] | ||||
| Taxonomic identifier | 9606 [NCBI] | ||||
| Taxonomic lineage | Eukaryota › Metazoa › Chordata › Craniata › Vertebrata › Euteleostomi › Mammalia › Eutheria › Euarchontoglires › Primates › Haplorrhini › Catarrhini › Hominidae › Homo![]() |
Protein attributes
| Sequence length | 815 AA. |
| Sequence status | Complete. |
| Protein existence | Evidence at protein level |
General annotation (Comments)
| Function | Involved in pH regulation to eliminate acids generated by active metabolism or to counter adverse environmental conditions. Major proton extruding system driven by the inward sodium ion chemical gradient. Plays an important role in signal transduction. Ref.11 Ref.15 Ref.18 |
| Subunit structure | Oligomer By similarity. Interacts with calmodulin and TESC. Interacts (via the juxtamembrane region of the cytoplasmic C-terminus domain) with CHP1; the interaction occurs at the plasma membrane in a calcium-dependent manner. Interacts with CHP2; the interaction occurs in a calcium-dependent manner. Ref.10 Ref.11 Ref.14 Ref.15 Ref.16 Ref.17 Ref.18 Ref.25 |
| Subcellular location | Membrane; Multi-pass membrane protein. Endoplasmic reticulum membrane; Multi-pass membrane protein By similarity. Cell membrane; Multi-pass membrane protein. Note: Colocalizes with CHP1 at the reticulum endoplasmic By similarity. Colocalizes with CHP1 and CHP2 at the plasma membrane. Ref.14 Ref.18 Ref.25 |
| Tissue specificity | Kidney and intestine. |
| Post-translational modification | O-glycosylated. Ref.9 Ubiquitinated, leading to its degradation by the proteasome. Ubiquitination is reduced by CHP1 By similarity. |
| Miscellaneous | Inhibited by amiloride and 5-amino-substituted derivatives and activated in a cooperative fashion by intracellular H+. In quiescent cells upon growth factor stimulation, the apparent affinity for internal H+ is increased, resulting in a persistent rise in cytoplasmic pH. |
| Sequence similarities | Belongs to the monovalent cation:proton antiporter 1 (CPA1) transporter (TC 2.A.36) family. [View classification] |
| Caution | The region between transmembrane regions M4 and M5 and between M6 and M7 (also termed intracellular loops IL2 and IL4, respectively) seem to be localized at least in part in the membrane. The hydrophobic region H10 is proposed to be located within the membrane. Although Ref.17 report that TESC-binding results in a decrease in activity, studies with rat SLC9A1 show that TESC-binding results in the maturation and accumulation of SLC9A1 at the cell surface. Although Ref.17 report that CHP1 and TESC bind to SLC9A1 at different sites, studies with rat SLC9A1 show that they bind at the same C-terminal site. |
| Biophysicochemical properties | pH dependence: Fully active at acidic pHs, the antiporter is virtually turned off at neutral pH. |
Ontologies
Alternative products
| This entry describes 2 isoforms produced by alternative splicing. [Align] [Select] | ||||||
| Isoform 1 (identifier: P19634-1) This isoform has been chosen as the 'canonical' sequence. All positional information in this entry refers to it. This is also the sequence that appears in the downloadable versions of the entry. | ||||||
| Isoform 2 (identifier: P19634-2) The sequence of this isoform differs from the canonical sequence as follows: 496-554: GMTIRPLVDL...HWKDKLNRFN → VLGQGRAGPC...FWASVSSIVK 555-815: Missing. | ||||||
| Note: No experimental confirmation available. |
Sequence annotation (Features)
| Feature key | Position(s) | Length | Description | Graphical view | Feature identifier | |||||||||||||||||||||||||||||
Molecule processing | ||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Chain | 1 – 815 | 815 | Sodium/hydrogen exchanger 1 | PRO_0000052347 | ||||||||||||||||||||||||||||||
Regions | ||||||||||||||||||||||||||||||||||
| Topological domain | 1 – 12 | 12 | Cytoplasmic Potential | |||||||||||||||||||||||||||||||
| Transmembrane | 13 – 33 | 21 | Helical; Name=M1; Potential | |||||||||||||||||||||||||||||||
| Topological domain | 34 – 105 | 72 | Extracellular Potential | |||||||||||||||||||||||||||||||
| Transmembrane | 106 – 127 | 22 | Helical; Name=M2; Potential | |||||||||||||||||||||||||||||||
| Topological domain | 128 – 129 | 2 | Cytoplasmic Potential | |||||||||||||||||||||||||||||||
| Transmembrane | 130 – 149 | 20 | Helical; Name=M3; Potential | |||||||||||||||||||||||||||||||
| Topological domain | 150 – 154 | 5 | Extracellular Potential | |||||||||||||||||||||||||||||||
| Transmembrane | 155 – 174 | 20 | Helical; Name=M4; Potential | |||||||||||||||||||||||||||||||
| Topological domain | 175 – 191 | 17 | Cytoplasmic Potential | |||||||||||||||||||||||||||||||
| Transmembrane | 192 – 211 | 20 | Helical; Name=M5; Potential | |||||||||||||||||||||||||||||||
| Topological domain | 212 – 227 | 16 | Extracellular Potential | |||||||||||||||||||||||||||||||
| Transmembrane | 228 – 247 | 20 | Helical; Name=M6; Potential | |||||||||||||||||||||||||||||||
| Topological domain | 248 – 256 | 9 | Cytoplasmic Potential | |||||||||||||||||||||||||||||||
| Transmembrane | 257 – 276 | 20 | Helical; Name=M7; Potential | |||||||||||||||||||||||||||||||
| Topological domain | 277 – 294 | 18 | Extracellular Potential | |||||||||||||||||||||||||||||||
| Transmembrane | 295 – 315 | 21 | Helical; Name=M8; Potential | |||||||||||||||||||||||||||||||
| Topological domain | 316 – 338 | 23 | Cytoplasmic Potential | |||||||||||||||||||||||||||||||
| Transmembrane | 339 – 358 | 20 | Helical; Name=M9; Potential | |||||||||||||||||||||||||||||||
| Topological domain | 359 – 381 | 23 | Extracellular Potential | |||||||||||||||||||||||||||||||
| Intramembrane | 382 – 402 | 21 | Name=H10; By similarity | |||||||||||||||||||||||||||||||
| Topological domain | 403 – 410 | 8 | Extracellular Potential | |||||||||||||||||||||||||||||||
| Transmembrane | 411 – 430 | 20 | Helical; Name=M10; Potential | |||||||||||||||||||||||||||||||
| Topological domain | 431 – 448 | 18 | Cytoplasmic Potential | |||||||||||||||||||||||||||||||
| Transmembrane | 449 – 470 | 22 | Helical; Name=M11; Potential | |||||||||||||||||||||||||||||||
| Topological domain | 471 – 479 | 9 | Extracellular Potential | |||||||||||||||||||||||||||||||
| Transmembrane | 480 – 499 | 20 | Helical; Name=M12; Potential | |||||||||||||||||||||||||||||||
| Topological domain | 500 – 815 | 316 | Cytoplasmic Potential | |||||||||||||||||||||||||||||||
| Region | 516 – 539 | 24 | Interaction with CHP2 | |||||||||||||||||||||||||||||||
Sites | ||||||||||||||||||||||||||||||||||
| Site | 161 | 1 | Channel pore-lining Probable | |||||||||||||||||||||||||||||||
| Site | 370 | 1 | Not glycosylated | |||||||||||||||||||||||||||||||
Amino acid modifications | ||||||||||||||||||||||||||||||||||
| Modified residue | 599 | 1 | Phosphoserine By similarity | |||||||||||||||||||||||||||||||
| Modified residue | 602 | 1 | Phosphoserine By similarity | |||||||||||||||||||||||||||||||
| Modified residue | 605 | 1 | Phosphoserine By similarity | |||||||||||||||||||||||||||||||
| Modified residue | 693 | 1 | Phosphoserine By similarity | |||||||||||||||||||||||||||||||
| Modified residue | 697 | 1 | Phosphoserine Ref.22 | |||||||||||||||||||||||||||||||
| Modified residue | 703 | 1 | Phosphoserine Ref.21 Ref.22 Ref.23 Ref.24 Ref.26 | |||||||||||||||||||||||||||||||
| Modified residue | 723 | 1 | Phosphoserine Ref.22 | |||||||||||||||||||||||||||||||
| Modified residue | 726 | 1 | Phosphoserine Ref.22 | |||||||||||||||||||||||||||||||
| Modified residue | 729 | 1 | Phosphoserine Ref.22 | |||||||||||||||||||||||||||||||
| Modified residue | 785 | 1 | Phosphoserine Ref.22 | |||||||||||||||||||||||||||||||
| Glycosylation | 75 | 1 | N-linked (GlcNAc...) Ref.9 | |||||||||||||||||||||||||||||||
Natural variations | ||||||||||||||||||||||||||||||||||
| Alternative sequence | 496 – 554 | 59 | GMTIR…LNRFN → VLGQGRAGPCLGDPHRLFPW KERKACDLKCDSSPSSTTNL LCDLGRATPPFWASVSSIVK in isoform 2. | VSP_022101 | ||||||||||||||||||||||||||||||
| Alternative sequence | 555 – 815 | 261 | Missing in isoform 2. | VSP_022102 | ||||||||||||||||||||||||||||||
| Natural variant | 682 | 1 | N → K. Corresponds to variant rs35703140 [ dbSNP | Ensembl ]. | VAR_050231 | ||||||||||||||||||||||||||||||
Experimental info | ||||||||||||||||||||||||||||||||||
| Mutagenesis | 155 | 1 | F → C: Almost complete loss of activity. Ref.27 | |||||||||||||||||||||||||||||||
| Mutagenesis | 156 | 1 | L → C: Almost complete loss of activity. Ref.27 | |||||||||||||||||||||||||||||||
| Mutagenesis | 157 | 1 | Q → C: Reduces activity. Ref.27 | |||||||||||||||||||||||||||||||
| Mutagenesis | 158 | 1 | S → C: Almost complete loss of activity. Ref.27 | |||||||||||||||||||||||||||||||
| Mutagenesis | 159 | 1 | D → C: Almost complete loss of activity. Ref.27 | |||||||||||||||||||||||||||||||
| Mutagenesis | 160 | 1 | V → C: Reduces activity. Ref.27 | |||||||||||||||||||||||||||||||
| Mutagenesis | 161 | 1 | F → C: Reduces activity. Ref.27 | |||||||||||||||||||||||||||||||
| Mutagenesis | 162 | 1 | F → C: Almost complete loss of activity. Ref.27 | |||||||||||||||||||||||||||||||
| Mutagenesis | 163 | 1 | L → C: Reduces activity. Ref.27 | |||||||||||||||||||||||||||||||
| Mutagenesis | 164 | 1 | F → C: Almost complete loss of activity. Ref.27 | |||||||||||||||||||||||||||||||
| Mutagenesis | 165 | 1 | L → C: Reduces activity. Ref.27 | |||||||||||||||||||||||||||||||
| Mutagenesis | 166 | 1 | L → C: Reduces activity. Ref.27 | |||||||||||||||||||||||||||||||
| Mutagenesis | 167 | 1 | P → A: Reduces activity. Ref.19 Ref.27 | |||||||||||||||||||||||||||||||
| Mutagenesis | 167 | 1 | P → C or G: Almost complete loss of activity. Reduces membrane localization. Ref.19 Ref.27 | |||||||||||||||||||||||||||||||
| Mutagenesis | 168 | 1 | P → A or C: Almost complete loss of activity. Ref.19 Ref.27 | |||||||||||||||||||||||||||||||
| Mutagenesis | 168 | 1 | P → G: Reduces activity. Ref.19 Ref.27 | |||||||||||||||||||||||||||||||
| Mutagenesis | 169 | 1 | I → C: Reduces activity. Ref.27 | |||||||||||||||||||||||||||||||
| Mutagenesis | 170 | 1 | I → C: Reduces activity. Ref.27 | |||||||||||||||||||||||||||||||
| Mutagenesis | 171 | 1 | L → C: Reduces activity. Ref.27 | |||||||||||||||||||||||||||||||
| Mutagenesis | 172 | 1 | D → C: Almost complete loss of activity. Ref.27 | |||||||||||||||||||||||||||||||
| Mutagenesis | 173 | 1 | A → C: Reduces activity. Ref.27 | |||||||||||||||||||||||||||||||
| Mutagenesis | 174 | 1 | G → C: Reduces activity. Ref.27 | |||||||||||||||||||||||||||||||
| Mutagenesis | 175 | 1 | Y → C: Almost complete loss of activity. Ref.27 | |||||||||||||||||||||||||||||||
| Mutagenesis | 176 | 1 | F → C: Almost complete loss of activity. Ref.27 | |||||||||||||||||||||||||||||||
| Mutagenesis | 177 | 1 | L → C: Reduces activity. Ref.27 | |||||||||||||||||||||||||||||||
| Mutagenesis | 178 | 1 | P → A: No effect. | |||||||||||||||||||||||||||||||
| Mutagenesis | 180 | 1 | R → C: Reduces activity. Ref.13 | |||||||||||||||||||||||||||||||
| Mutagenesis | 181 | 1 | Q → C: Reduces activity. Ref.13 | |||||||||||||||||||||||||||||||
| Mutagenesis | 518 | 1 | I → Q: Reduces interaction with CHP1 and the exchange activity; when associated with Q-522. Ref.15 | |||||||||||||||||||||||||||||||
| Mutagenesis | 522 | 1 | I → Q: Reduces interaction with CHP1 and the exchange activity; when associated with Q-518. Ref.15 | |||||||||||||||||||||||||||||||
| Mutagenesis | 526 – 531 | 6 | FLDHLL → QQDHQQ: Inhibits interaction with CHP1 and the exchange activity. CHPI does not localize at the cell membrane. Ref.15 | |||||||||||||||||||||||||||||||
| Mutagenesis | 526 – 531 | 6 | FLDHLL → RRDHRR: Inhibits interaction with CHP1 and the exchange activity. CHPI does not localize at the cell membrane. Ref.15 | |||||||||||||||||||||||||||||||
| Mutagenesis | 526 | 1 | F → Q: Reduces interaction with CHP1 and the exchange activity; when associated with Q-527. Ref.15 | |||||||||||||||||||||||||||||||
| Mutagenesis | 527 | 1 | L → Q: Reduces interaction with CHP1 and the exchange activity; when associated with Q-526. Ref.15 | |||||||||||||||||||||||||||||||
| Mutagenesis | 530 | 1 | L → Q: Reduces interaction with CHP1 and the exchange activity; when associated with Q-531. Ref.15 | |||||||||||||||||||||||||||||||
| Mutagenesis | 531 | 1 | L → Q: Reduces interaction with CHP1 and the exchange activity; when associated with Q-530. Ref.15 | |||||||||||||||||||||||||||||||
| Mutagenesis | 534 | 1 | I → D or K: Strongly reduced interaction with CHP2. Ref.29 | |||||||||||||||||||||||||||||||
| Mutagenesis | 537 | 1 | I → K: Strongly reduced interaction with CHP2. Ref.29 | |||||||||||||||||||||||||||||||
Secondary structure | ||||||||||||||||||||||||||||||||||
Helix Strand Turn | ||||||||||||||||||||||||||||||||||
| Helix | 162 – 165 | 4 | ||||||||||||||||||||||||||||||||
| Helix | 171 – 174 | 4 | ||||||||||||||||||||||||||||||||
| Helix | 177 – 180 | 4 | ||||||||||||||||||||||||||||||||
| Helix | 231 – 234 | 4 | ||||||||||||||||||||||||||||||||
| Helix | 239 – 249 | 11 | ||||||||||||||||||||||||||||||||
| Helix | 256 – 259 | 4 | ||||||||||||||||||||||||||||||||
| Turn | 260 – 274 | 15 | ||||||||||||||||||||||||||||||||
| Helix | 448 – 451 | 4 | ||||||||||||||||||||||||||||||||
| Turn | 452 – 455 | 4 | ||||||||||||||||||||||||||||||||
| Helix | 459 – 471 | 13 | ||||||||||||||||||||||||||||||||
| Helix | 518 – 538 | 21 | ||||||||||||||||||||||||||||||||
| Helix | 625 – 651 | 27 | ||||||||||||||||||||||||||||||||
| Helix | 658 – 681 | 24 | ||||||||||||||||||||||||||||||||
| Turn | 682 – 684 | 3 | ||||||||||||||||||||||||||||||||
Sequences
| ||||||||||||||||||||||||
References
| « Hide 'large scale' references | |
| [1] | "Molecular cloning, primary structure, and expression of the human growth factor-activatable Na+/H+ antiporter." Sardet C., Franchi A., Pouyssegur J. Cell 56:271-280(1989) [PubMed] [Europe PMC] [Abstract] Cited for: NUCLEOTIDE SEQUENCE [MRNA]. Tissue: Kidney. |
| [2] | "Growth factors induce phosphorylation of the Na+/H+ antiporter, glycoprotein of 110 kD." Sardet C., Counillon L., Franchi A., Pouyssegur J. Science 247:723-726(1990) [PubMed] [Europe PMC] [Abstract] Cited for: NUCLEOTIDE SEQUENCE [MRNA]. Tissue: Kidney. |
| [3] | "Molecular cloning and expression of a cDNA encoding the rabbit ileal villus cell basolateral membrane Na+/H+ exchanger." Tse C.-M., Ma A.I., Yang V.W., Watson A.J.M., Levine S., Montrose M.H., Potter J., Sardet C., Pouyssegur J., Donowitz M. EMBO J. 10:1957-1967(1991) [PubMed] [Europe PMC] [Abstract] Cited for: SEQUENCE REVISION. |
| [4] | "Cloning and analysis of the human myocardial Na+/H+ exchanger." Fliegel L., Dyck J.R., Wang H., Fong C., Haworth R.S. Mol. Cell. Biochem. 125:137-143(1993) [PubMed] [Europe PMC] [Abstract] Cited for: NUCLEOTIDE SEQUENCE [MRNA]. Tissue: Heart. |
| [5] | "Silent polymorphisms within the coding region of human sodium/hydrogen exchanger isoform-1 cDNA in peripheral blood mononuclear cells of leukemia patients: a comparison with healthy controls." Garden O.A., Musk P., Worthington-White D.A., Dewey M.J., Rich I.N. Cancer Genet. Cytogenet. 120:37-43(2000) [PubMed] [Europe PMC] [Abstract] Cited for: NUCLEOTIDE SEQUENCE [MRNA]. |
| [6] | "The DNA sequence and biological annotation of human chromosome 1." Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A., Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C., Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K. Bentley D.R.Nature 441:315-321(2006) [PubMed] [Europe PMC] [Abstract] Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. |
| [7] | Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., Turner R. Venter J.C.Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. |
| [8] | "The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC)." The MGC Project Team Genome Res. 14:2121-2127(2004) [PubMed] [Europe PMC] [Abstract] Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2). Tissue: Placenta. |
| [9] | "The Na+/H+ exchanger NHE-1 possesses N- and O-linked glycosylation restricted to the first N-terminal extracellular domain." Counillon L., Pouyssegur J., Reithmeier R.A. Biochemistry 33:10463-10469(1994) [PubMed] [Europe PMC] [Abstract] Cited for: GLYCOSYLATION AT ASN-75, O-LINKED GLYCOSYLATION. |
| [10] | "Coimmunoprecipitation of a 24-kDa protein with NHE1, the ubiquitous isoform of the Na+/H+ exchanger." Goss G., Orlowski J., Grinstein S. Am. J. Physiol. 270:C1493-C1502(1996) [PubMed] [Europe PMC] [Abstract] Cited for: INTERACTION WITH CHP1. |
| [11] | "A calcineurin homologous protein inhibits GTPase-stimulated Na-H exchange." Lin X., Barber D.L. Proc. Natl. Acad. Sci. U.S.A. 93:12631-12636(1996) [PubMed] [Europe PMC] [Abstract] Cited for: FUNCTION IN PH REGULATION, INTERACTION WITH CHP1. |
| [12] | "Topological analysis of NHE1, the ubiquitous Na+/H+ exchanger using chymotryptic cleavage." Shrode L.D., Gan B.S., D'Souza S.J., Orlowski J., Grinstein S. Am. J. Physiol. 275:C431-C439(1998) [PubMed] [Europe PMC] [Abstract] Cited for: TOPOLOGY. |
| [13] | "A novel topology model of the human Na(+)/H(+) exchanger isoform 1." Wakabayashi S., Pang T., Su X., Shigekawa M. J. Biol. Chem. 275:7942-7949(2000) [PubMed] [Europe PMC] [Abstract] Cited for: TOPOLOGY, MUTAGENESIS OF ARG-180 AND GLN-181. |
| [14] | "Human homolog of mouse tescalcin associates with Na(+)/H(+) exchanger type-1." Mailaender J., Mueller-Esterl W., Dedio J. FEBS Lett. 507:331-335(2001) [PubMed] [Europe PMC] [Abstract] Cited for: INTERACTION WITH TESC, SUBCELLULAR LOCATION. |
| [15] | "Calcineurin homologous protein as an essential cofactor for Na+/H+ exchangers." Pang T., Su X., Wakabayashi S., Shigekawa M. J. Biol. Chem. 276:17367-17372(2001) [PubMed] [Europe PMC] [Abstract] Cited for: FUNCTION, INTERACTION WITH CHP1, MUTAGENESIS OF ILE-518; ILE-522; PHE-526; LEU-527; LEU-530; LEU-531 AND 526-PHE--LEU-531. |
| [16] | "Expression of calcineurin B homologous protein 2 protects serum deprivation-induced cell death by serum-independent activation of Na+/H+ exchanger." Pang T., Wakabayashi S., Shigekawa M. J. Biol. Chem. 277:43771-43777(2002) [PubMed] [Europe PMC] [Abstract] Cited for: INTERACTION WITH CHP2. |
| [17] | "The Na+/H+ exchanger cytoplasmic tail: structure, function, and interactions with tescalcin." Li X., Liu Y., Kay C.M., Muller-Esterl W., Fliegel L. Biochemistry 42:7448-7456(2003) [PubMed] [Europe PMC] [Abstract] Cited for: INTERACTION WITH TESC AND CALMODULIN. |
| [18] | "Role of calcineurin B homologous protein in pH regulation by the Na+/H+ exchanger 1: tightly bound Ca2+ ions as important structural elements." Pang T., Hisamitsu T., Mori H., Shigekawa M., Wakabayashi S. Biochemistry 43:3628-3636(2004) [PubMed] [Europe PMC] [Abstract] Cited for: FUNCTION IN PH REGULATION, INTERACTION WITH CHP1, SUBCELLULAR LOCATION. |
| [19] | "Proline residues in transmembrane segment IV are critical for activity, expression and targeting of the Na+/H+ exchanger isoform 1." Slepkov E.R., Chow S., Lemieux M.J., Fliegel L. Biochem. J. 379:31-38(2004) [PubMed] [Europe PMC] [Abstract] Cited for: MUTAGENESIS OF PRO-167 AND PRO-168. |
| [20] | "ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage." Matsuoka S., Ballif B.A., Smogorzewska A., McDonald E.R. III, Hurov K.E., Luo J., Bakalarski C.E., Zhao Z., Solimini N., Lerenthal Y., Shiloh Y., Gygi S.P., Elledge S.J. Science 316:1160-1166(2007) [PubMed] [Europe PMC] [Abstract] Cited for: IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. Tissue: Embryonic kidney. |
| [21] | "Phosphoproteome of resting human platelets." Zahedi R.P., Lewandrowski U., Wiesner J., Wortelkamp S., Moebius J., Schuetz C., Walter U., Gambaryan S., Sickmann A. J. Proteome Res. 7:526-534(2008) [PubMed] [Europe PMC] [Abstract] Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-703, MASS SPECTROMETRY. Tissue: Platelet. |
| [22] | "A quantitative atlas of mitotic phosphorylation." Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., Elledge S.J., Gygi S.P. Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008) [PubMed] [Europe PMC] [Abstract] Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-697; SER-703; SER-723; SER-726; SER-729 AND SER-785, MASS SPECTROMETRY. Tissue: Cervix carcinoma. |
| [23] | "Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions." Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., Rodionov V., Han D.K. Sci. Signal. 2:RA46-RA46(2009) [PubMed] [Europe PMC] [Abstract] Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-703, MASS SPECTROMETRY. Tissue: Leukemic T-cell. |
| [24] | "Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis." Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M. Sci. Signal. 3:RA3-RA3(2010) [PubMed] [Europe PMC] [Abstract] Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-703, MASS SPECTROMETRY. Tissue: Cervix carcinoma. |
| [25] | "Nuclear accumulation of calcineurin B homologous protein 2 (CHP2) results in enhanced proliferation of tumor cells." Li Q.H., Wang L.H., Lin Y.N., Chang G.Q., Li H.W., Jin W.N., Hu R.H., Pang T.X. Genes Cells 16:416-426(2011) [PubMed] [Europe PMC] [Abstract] Cited for: INTERACTION WITH CHP2, SUBCELLULAR LOCATION. |
| [26] | "System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation." Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B. Sci. Signal. 4:RS3-RS3(2011) [PubMed] [Europe PMC] [Abstract] Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-703, MASS SPECTROMETRY. |
| [27] | "Structural and functional characterization of transmembrane segment IV of the NHE1 isoform of the Na+/H+ exchanger." Slepkov E.R., Rainey J.K., Li X., Liu Y., Cheng F.J., Lindhout D.A., Sykes B.D., Fliegel L. J. Biol. Chem. 280:17863-17872(2005) [PubMed] [Europe PMC] [Abstract] Cited for: STRUCTURE BY NMR OF 155-180, MUTAGENESIS OF PHE-155; LEU-156; GLN-157; SER-158; ASP-159; VAL-160; PHE-161; PHE-162; LEU-163; PHE-164; LEU-165; LEU-166; PRO-167; PRO-168; ILE-169; ILE-170; LEU-171; ASP-172; ALA-173; GLY-174; TYR-175; PHE-176 AND LEU-177. |
| [28] | "Crystallization and preliminary crystallographic analysis of the human calcineurin homologous protein CHP2 bound to the cytoplasmic region of the Na+/H+ exchanger NHE1." Ben Ammar Y., Takeda S., Sugawara M., Miyano M., Mori H., Wakabayashi S. Acta Crystallogr. F 61:956-958(2005) [PubMed] [Europe PMC] [Abstract] Cited for: PRELIMINARY X-RAY CRYSTALLOGRAPHY OF 503-545 IN COMPLEX WITH CHP2. |
| [29] | "Crystal structure of CHP2 complexed with NHE1-cytosolic region and an implication for pH regulation." Ammar Y.B., Takeda S., Hisamitsu T., Mori H., Wakabayashi S. EMBO J. 25:2315-2325(2006) [PubMed] [Europe PMC] [Abstract] Cited for: X-RAY CRYSTALLOGRAPHY (2.7 ANGSTROMS) OF 503-545 IN COMPLEX WITH CHP2, MUTAGENESIS OF ILE-534 AND ILE-537. |
| [30] | "Solution structure of the cytoplasmic region of Na+/H+ exchanger 1 complexed with essential cofactor calcineurin B homologous protein 1." Mishima M., Wakabayashi S., Kojima C. J. Biol. Chem. 282:2741-2751(2007) [PubMed] [Europe PMC] [Abstract] Cited for: STRUCTURE BY NMR OF 503-545 IN COMPLEX WITH CHP1. |
| + | Additional computationally mapped references. |
Cross-references
Sequence databases | |||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EMBL GenBank DDBJ | M81768 mRNA. Translation: AAB59460.1. Sequence problems. S68616 mRNA. Translation: AAC60606.1. AF141350 mRNA. Translation: AAF21350.1. AF141351 mRNA. Translation: AAF21351.1. AF141352 mRNA. Translation: AAF21352.1. AF141353 mRNA. Translation: AAF21353.1. AF141354 mRNA. Translation: AAF21354.1. AF141355 mRNA. Translation: AAF21355.1. AF141356 mRNA. Translation: AAF21356.1. AF141357 mRNA. Translation: AAF21357.1. AF141358 mRNA. Translation: AAF21358.1. AF141359 mRNA. Translation: AAF21359.1. AF146430 mRNA. Translation: AAF25592.1. AF146431 mRNA. Translation: AAF25593.1. AF146432 mRNA. Translation: AAF25594.1. AF146433 mRNA. Translation: AAF25595.1. AF146434 mRNA. Translation: AAF25596.1. AF146435 mRNA. Translation: AAF25597.1. AF146436 mRNA. Translation: AAF25598.1. AF146437 mRNA. Translation: AAF25599.1. AF146438 mRNA. Translation: AAF25600.1. AF146439 mRNA. Translation: AAF25601.1. AL590640, AL137860 Genomic DNA. Translation: CAH73555.1. AL590640, AL137860 Genomic DNA. Translation: CAH73556.1. AL137860, AL590640 Genomic DNA. Translation: CAI22089.1. AL137860, AL590640 Genomic DNA. Translation: CAI22090.1. CH471059 Genomic DNA. Translation: EAX07773.1. CH471059 Genomic DNA. Translation: EAX07774.1. BC012121 mRNA. Translation: AAH12121.1. | ||||||||||||||||||||||||||||||||||||||||||||||||
| IPI | IPI00020060. IPI00644335. | ||||||||||||||||||||||||||||||||||||||||||||||||
| PIR | I57487. | ||||||||||||||||||||||||||||||||||||||||||||||||
| RefSeq | NP_003038.2. NM_003047.4. | ||||||||||||||||||||||||||||||||||||||||||||||||
| UniGene | Hs.469116. Hs.91389. | ||||||||||||||||||||||||||||||||||||||||||||||||
3D structure databases | |||||||||||||||||||||||||||||||||||||||||||||||||
| PDBe RCSB PDB PDBj |
| ||||||||||||||||||||||||||||||||||||||||||||||||
| ProteinModelPortal | P19634. | ||||||||||||||||||||||||||||||||||||||||||||||||
| ModBase | Search... | ||||||||||||||||||||||||||||||||||||||||||||||||
Protein-protein interaction databases | |||||||||||||||||||||||||||||||||||||||||||||||||
| IntAct | P19634. 4 interactions. | ||||||||||||||||||||||||||||||||||||||||||||||||
| MINT | MINT-194742. | ||||||||||||||||||||||||||||||||||||||||||||||||
| STRING | 9606.ENSP00000263980. | ||||||||||||||||||||||||||||||||||||||||||||||||
PTM databases | |||||||||||||||||||||||||||||||||||||||||||||||||
| PhosphoSite | P19634. | ||||||||||||||||||||||||||||||||||||||||||||||||
Polymorphism databases | |||||||||||||||||||||||||||||||||||||||||||||||||
| DMDM | 127809. | ||||||||||||||||||||||||||||||||||||||||||||||||
Proteomic databases | |||||||||||||||||||||||||||||||||||||||||||||||||
| PaxDb | P19634. | ||||||||||||||||||||||||||||||||||||||||||||||||
| PRIDE | P19634. | ||||||||||||||||||||||||||||||||||||||||||||||||
Protocols and materials databases | |||||||||||||||||||||||||||||||||||||||||||||||||
| StructuralBiologyKnowledgebase | Search... | ||||||||||||||||||||||||||||||||||||||||||||||||
Genome annotation databases | |||||||||||||||||||||||||||||||||||||||||||||||||
| Ensembl | ENST00000263980; ENSP00000263980; ENSG00000090020. ENST00000374086; ENSP00000363199; ENSG00000090020. | ||||||||||||||||||||||||||||||||||||||||||||||||
| GeneID | 6548. | ||||||||||||||||||||||||||||||||||||||||||||||||
| KEGG | hsa:6548. | ||||||||||||||||||||||||||||||||||||||||||||||||
| UCSC | uc001bnm.3. human. uc001bnn.2. human. | ||||||||||||||||||||||||||||||||||||||||||||||||
Organism-specific databases | |||||||||||||||||||||||||||||||||||||||||||||||||
| CTD | 6548. | ||||||||||||||||||||||||||||||||||||||||||||||||
| GeneCards | GC01M027425. | ||||||||||||||||||||||||||||||||||||||||||||||||
| HGNC | HGNC:11071. SLC9A1. | ||||||||||||||||||||||||||||||||||||||||||||||||
| HPA | CAB022371. | ||||||||||||||||||||||||||||||||||||||||||||||||
| MIM | 107310. gene. | ||||||||||||||||||||||||||||||||||||||||||||||||
| neXtProt | NX_P19634. | ||||||||||||||||||||||||||||||||||||||||||||||||
| PharmGKB | PA35928. | ||||||||||||||||||||||||||||||||||||||||||||||||
| GenAtlas | Search... | ||||||||||||||||||||||||||||||||||||||||||||||||
Phylogenomic databases | |||||||||||||||||||||||||||||||||||||||||||||||||
| eggNOG | COG0025. | ||||||||||||||||||||||||||||||||||||||||||||||||
| HOGENOM | HOG000247044. | ||||||||||||||||||||||||||||||||||||||||||||||||
| HOVERGEN | HBG052615. | ||||||||||||||||||||||||||||||||||||||||||||||||
| InParanoid | P19634. | ||||||||||||||||||||||||||||||||||||||||||||||||
| KO | K05742. | ||||||||||||||||||||||||||||||||||||||||||||||||
| OMA | MELMIST. | ||||||||||||||||||||||||||||||||||||||||||||||||
| OrthoDB | EOG4FR0R9. | ||||||||||||||||||||||||||||||||||||||||||||||||
| PhylomeDB | P19634. | ||||||||||||||||||||||||||||||||||||||||||||||||
Enzyme and pathway databases | |||||||||||||||||||||||||||||||||||||||||||||||||
| Pathway_Interaction_DB | endothelinpathway. Endothelins. p38alphabetadownstreampathway. Signaling mediated by p38-alpha and p38-beta. | ||||||||||||||||||||||||||||||||||||||||||||||||
| Reactome | REACT_111217. Metabolism. REACT_116125. Disease. REACT_15518. Transmembrane transport of small molecules. | ||||||||||||||||||||||||||||||||||||||||||||||||
Gene expression databases | |||||||||||||||||||||||||||||||||||||||||||||||||
| ArrayExpress | P19634. | ||||||||||||||||||||||||||||||||||||||||||||||||
| Bgee | P19634. | ||||||||||||||||||||||||||||||||||||||||||||||||
| CleanEx | HS_SLC9A1. | ||||||||||||||||||||||||||||||||||||||||||||||||
| Genevestigator | P19634. | ||||||||||||||||||||||||||||||||||||||||||||||||
| GermOnline | ENSG00000090020. Homo sapiens. | ||||||||||||||||||||||||||||||||||||||||||||||||
Family and domain databases | |||||||||||||||||||||||||||||||||||||||||||||||||
| InterPro | IPR006153. Cation/H_exchanger. IPR018422. Cation/H_exchanger_CPA1. IPR001970. Na/H_exchanger_1. IPR004709. NaH_exchanger. [Graphical view] | ||||||||||||||||||||||||||||||||||||||||||||||||
| PANTHER | PTHR10110. PTHR10110. 1 hit. | ||||||||||||||||||||||||||||||||||||||||||||||||
| Pfam | PF00999. Na_H_Exchanger. 1 hit. [Graphical view] | ||||||||||||||||||||||||||||||||||||||||||||||||
| PRINTS | PR01084. NAHEXCHNGR. PR01085. NAHEXCHNGR1. | ||||||||||||||||||||||||||||||||||||||||||||||||
| TIGRFAMs | TIGR00840. b_cpa1. 1 hit. | ||||||||||||||||||||||||||||||||||||||||||||||||
| ProtoNet | Search... | ||||||||||||||||||||||||||||||||||||||||||||||||
Other | |||||||||||||||||||||||||||||||||||||||||||||||||
| BindingDB | P19634. | ||||||||||||||||||||||||||||||||||||||||||||||||
| ChEMBL | CHEMBL2781. | ||||||||||||||||||||||||||||||||||||||||||||||||
| ChiTaRS | SLC9A1. human. | ||||||||||||||||||||||||||||||||||||||||||||||||
| DrugBank | DB00594. Amiloride. | ||||||||||||||||||||||||||||||||||||||||||||||||
| EvolutionaryTrace | P19634. | ||||||||||||||||||||||||||||||||||||||||||||||||
| GenomeRNAi | 6548. | ||||||||||||||||||||||||||||||||||||||||||||||||
| NextBio | 25485. | ||||||||||||||||||||||||||||||||||||||||||||||||
| SOURCE | Search... | ||||||||||||||||||||||||||||||||||||||||||||||||
Entry information
| Entry name | SL9A1_HUMAN | ||||||||
| Accession | Primary (citable) accession number: P19634 Secondary accession number(s): B1ALD6, D3DPL4, Q96EM2 | ||||||||
| Entry history |
| ||||||||
| Entry status | Reviewed (UniProtKB/Swiss-Prot) | ||||||||
| Annotation program | Chordata Protein Annotation Program | ||||||||
| Disclaimer | Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. It is not in any way intended to be used as a substitute for professional medical advice, diagnosis, treatment or care. | ||||||||
Relevant documents
| Human chromosome 1 Human chromosome 1: entries, gene names and cross-references to MIM |
| Human entries with polymorphisms or disease mutations List of human entries with polymorphisms or disease mutations |
| Human polymorphisms and disease mutations Index of human polymorphisms and disease mutations |
| MIM cross-references Online Mendelian Inheritance in Man (MIM) cross-references in UniProtKB/Swiss-Prot |
| PDB cross-references Index of Protein Data Bank (PDB) cross-references |
| SIMILARITY comments Index of protein domains and families |

Clusters with
